Azimilide inhibits multiple cardiac potassium currents in human atial myocytes

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 7, Issue 4, 2002, Pages 255-264

  Chen, Fuhua ^a   Esmailian, Fardad ^a   Sun, Wei ^b   Wetzel, Glenn T ^a   Sarma, Jonnalagedda S M ^b   Singh, Bramah N ^b   Klitzner, Thomas S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Atrial fibrillation; Azimilide; Class III antiarrhythmics; Flutter; Human heart cells; Potassium currents

Indexed keywords

AZIMILIDE; INWARDLY RECTIFYING POTASSIUM CHANNEL; IMIDAZOLE DERIVATIVE; IMIDAZOLIDINE DERIVATIVE; PIPERAZINE DERIVATIVE; POTASSIUM CHANNEL;

ACTION POTENTIAL; ARTICLE; CONTROLLED STUDY; ELECTRIC CAPACITANCE; ELECTROPHYSIOLOGY; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HUMAN; HUMAN CELL; MEMBRANE POTENTIAL; POTASSIUM CURRENT; PRIORITY JOURNAL; TORSADE DES POINTES; VOLTAGE CLAMP; ANALYSIS OF VARIANCE; CELL MEMBRANE POTENTIAL; CYTOLOGY; DRUG EFFECT; HEART ATRIUM; HEART MUSCLE CELL; PHYSIOLOGY;

ANALYSIS OF VARIANCE; HEART ATRIA; IMIDAZOLES; IMIDAZOLIDINES; MEMBRANE POTENTIALS; MYOCYTES, CARDIAC; PIPERAZINES; POTASSIUM CHANNELS;

EID: 0036819066     PISSN: 10742484     EISSN: None     Source Type: Journal    
DOI: 10.1177/107424840200700409     Document Type: Article

References (18)

1. Connolly SJ, Schnell DJ, Page RL, et al. Dose-response relations of azimilide in the management of symptomatic, recurrent, atrial fibrillation. Am J Cardiol 88:974-979, 2001
2. Black SC, Butterfield JL, Lucchesi BR. Protection against programmed electrical stimulation-induced ventricular tachycardia and sudden cardiac death by NE-10064, a class III antiarrhythmic drug. J Cardiovasc Pharmacol 22:810-818, 1993
3. Drexler AP, Micklas JM, Brooks RR. Suppression of inducible ventricular arrhythmias by intravenous azimilide in dogs with previous myocardial infarction. J Cardiovasc Pharmacol 28:848-855, 1996
4. Brooks RR, Carpenter JF, Miller KE, Maynard AE. Efficacy of the class III antiarrhythmic agent azimilide in rodent models of ventricular arrhythmia. Proc Soc Exp Biol Med 212:84-93, 1996
5. Restivo M, Hegazy M, Caref EB, et al. Effects of azimilide dihydrochloride on circus movement atrial flutter in the canine sterile pericarditis model. J Cardiovasc Electrophysiol 7:612-624, 1996
6. Nattel S, Liu L, St-Georges D. Effects of the novel antiarrhythmic agent azimilide on experimental atrial fibrillation and atrial electrophysiologic properties. Cardiovasc Res 37:627-635, 1998
7. Fermini B, Jurkiewicz NK, Jow B, et al. Use-dependent effects of the class III antiarrhythmic agent NE-10064 (azimilide) on cardiac repolarization: Block of delayed rectifier potassium and L-type calcium currents. J Cardiovasc Pharmacol 26:259-271, 1995
8. Yao JA, Tseng GN. Azimilide (NE-10064) can prolong or shorten the action potential duration in canine ventricular myocytes: Dependence on blockade of K, Ca, and Na channels. J Cardiovasc Electrophysiol 8:184-198, 1997
9. Karam R, Marcello S, Brooks RR, et al. Azimilide dihydrochloride, a novel antiarrhythmic agent. Am J Cardiol 81:40D-46D, 1998
10. Camm AJ, Karam R, Pratt CM. The azimilide post-infarct survival evaluation (ALIVE) trial. Am J Cardiol 81:35D-39D, 1998
11. Wang Z, Fermini B, Nattel S, Delayed rectifier outward current and repolarization in human atrial myocytes. Circ Res 73:276-285, 1993
12. Chen F, Wetzel GT, Friedman WF, Klitzner TS. Single channel recording of inwardly rectifying potassium currents in developing myocardium. J Mol Cell Cardiol 23:259-267, 1991
13. i2α gene knockout mouse heart. Am J Physiol (Heart Circ Physiol) 280:H1989-1995, 2001
14. Pritchett EL, Schulte MC, Schnell D, Azimilide Supraventricular Arrhythmia Program 3 (SVA-3) Investigators, et al. Effects of azimilide on heart rate and ECG conduction intervals during sinus rhythm in patients with a history of atrial fibrillation. J Clin Pharmacol 42:388-394, 2002
15. Phillips L, Grasela TH, Agnew JR, et al. A population pharmacokinetic-pharmacodynamic analysis and model validation of azimilide. Clin Pharmacol Ther 70:370-483, 2001
16. Singh BN, Sarma JSM. Mechanism of action of antiarrhythmic drugs relative to the origin and perpetuation of cardiac arrhythmias. J Cardiovasc Pharmacol Therapeut 6(1):69-87, 2001
17. Verdun SC, Van Opstal, Leunissen, JD, Vois MA. Assessment of the pro-arrhythmic potential of antiarrhythmic drugs: An experimental: Approach. J Cardiovasc Pharmacol Therapeut 6(1):89-97, 2001
18. Nattel S, Singh BN. Evolution, mechanisms, and classification of antiarrhythmic drugs: Focus on class III agents. Am J Cardiol 84:11R-19R, 1999